Phosphorus is a key component of bone, and a deficiency results in poor mineralization along with other systemic symptoms of hypophosphatemia. Various causes of hypophosphatemia with renal wasting of phosphorus have been identified. These include the Fanconi syndrome, various genetic mutations of fibroblast growth factor 23 (FGF23) handling and the sodium/phosphate cotransporter, and those due to FGF23 secretion by mesenchymal tumors. Depending on the cause, vitamin D metabolism may also be impaired, which may amplify the deficiency in phosphorus and render treatment more challenging. Here, we report a case of hypophosphatemia and multiple stress fractures in a 20-year-old male college student living with chronic bone pain and anxiety about suffering further fractures. We further review the literature regarding this spectrum.

Keywords:
Osteomalacia, Fibroblast growth factor 23, Phosphorus
1.
Bringhurst R, et al: Bone and mineral metabolism in health and disease; in Kasper D, et al (eds): Harrison's Principles of Internal Medicine, ed 19. New York, McGraw-Hill, 2015.
2.
Shoback D, Sellmeyer D, Bikle DD: Metabolic bone disease; in Gardner DG, Shoback D (eds): Greenspan's Basic & Clinical Endocrinology, ed 9. New York, McGraw-Hill, 2011, chapter 8.
3.
Liu S, Quarles LD: How fibroblast growth factor 23 works. J Am Soc Nephrol 2007;18:1637-1647.
4.
David V, Dai B, Martin A, Huang J, et al: Calcium regulates FGF-23 expression in bone. Endocrinology 2013;154:4469-4482.
5.
Lederer E: Renal phosphate transporters. Curr Opin Nephrol Hypertens 2014;23:502-506.
6.
Kuro-o M: Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006;15:437.
7.
Liu S, Tang W, Zhou J, et al: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-1315.
8.
Yamashita T, Konishi M, Miyake A, et al: Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 2002:277;28265-28270.
9.
Carpenter TO: Disorders of phosphate metabolism; in De Groot LJ, Beck-Peccoz P, Chrousos G, et al (eds): Endotext. South Dartmouth, MDText.com, 2000. http://www.ncbi.nlm.nih.gov/books/NBK279172/ (updated Aug 17, 2014).
10.
Rowe PS: The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 2004;15:264-281.
11.
Lorenz-Deperieux B, Benet-Pages A, Eckstein G, et al: Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotranporter gene SLC43A3. Am J Hum Genet 2006;78:193-201.
12.
Jyothsna G, Baum M: Genetic disorders of phosphate regulation. Pediatr Nephrol 2012;27:1477-1487.
13.
Weber T, Liu S: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003;18:1227-1234.
14.
Gupta D, Brietzke S, Hayden MR, Sowers JR: Phosphate metabolism in cardiorenal metabolic disease. Cardiorenal Med 2011;1:261-270.
15.
Imel EA, Econs MJ: Approach to the hypophosphatemic patient. J Clin Endocrinol Metab 2012;97:696-706.
16.
Recker RR: Bone biopsy and histomorphometry in clinical practice; in Rose CJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed 7. Washington, American Society of Bone and Mineral Research, 2008, p 180.
17.
Linglart A, Biosse-Duplan M, Briot K, et al: Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 2014:1:3;13-30.
18.
Ovejero D, Lim YH, Boyce AM, et al: Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. Osteoporos Int 2016, Epub ahead of print.
19.
Memon I, Norris KC, Bomback AS, et al: The association between parathyroid hormone levels and hemoglobin in diabetic and nondiabetic participants in the National Kidney Foundation's Kidney Early Evaluation Program. Cardiorenal Med 2013;3:120-127.
20.
Saab G, Whaley-Connell A, Bombeck A, et al: The association between parathyroid hormone levels and the cardiorenal metabolic syndrome in non-diabetic chronic kidney disease. Cardiorenal Med 2011;1:123-130.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.